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ess: mcazzola@qubisoftSummary Respiratory tract infections caused by both viruses and/or atypical
bacteria are involved in the pathogenesis of asthma. In particular, several viruses
such as respiratory syncytial virus, rhinovirus and influenza/parainfluenza viruses
may favour the expression of the asthmatic phenotype, being also implicated in the
induction of disease exacerbations. Within this pathological context, a significant
role can also be played by airway bacterial colonizations and infections due to
Chlamydiae and Mycoplasms. All these microbial agents probably interfere with
complex immunological pathways, thus contributing to induce and exacerbate
asthma in genetically predisposed individuals.
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Asthma is a chronic inflammatory airway disease
characterized by bronchial hyper-responsiveness to
a wide range of stimuli, recurrent episodes of
wheezing, breathlessness, chest tightness and
coughing, which are associated with reversible
airflow limitation.1 The important medical, social
and economical implications of asthma depend on
its very large epidemiological impact, in that over
150 million people worldwide are affected by this
disease, whose prevalence is on the rise especially
in the industrialized countries.2 Such alarming
numbers are prompting huge investments of finan-
cial and human resources, aimed at further
elucidating the pathogenic mechanisms underlying
asthma, as well as at developing new and more
effective anti-asthma treatments.
Current clinical and experimental evidence im-
plies that the two essential components of the
asthmatic phenotype include bronchial inflamma-
tion, mainly involving T lymphocytes, eosinophils
and mast cells, and airway remodelling, character-
ized by structural changes spanning throughout
epithelial lining, subepithelial mesenchymal layers,
airway smooth muscle, and bronchial vessels.3
These pathophysiologic patterns arise from an
intricate network of interactions between genetic
and environmental factors, including allergens,
pollutants, and infectious agents. With regard to
the latter, their role is indeed very intriguing, in
that it has been hypothesized that respiratory
infections, in addition to promoting both the
development and the exacerbations of asthma,
might also exert a protective effect against this
disease and atopy.4,5 Therefore, the aim of this
review is to provide a synthetic update about
the complex relationships between asthma and
respiratory infections caused by either viruses or
bacteria.Asthma and viral infections
In both children and adults, viral infections of the
airways may be associated with the development of
chronic asthma, as well as with acute disease
exacerbations.6 These associations can now be
reliably confirmed by currently available diagnos-
tic, molecular tools such as enzymatic amplification
of viral nucleic acids through polymerase chain
reaction (PCR).7 Although PCR is not yet widely
used in routine medical practice, this technique is
very useful for identifying respiratory viruses,
especially when performed on samples of inducedsputum, thus being much more efficient than
traditional serology and immunofluorescence. With
regard to the pathogenesis of asthma and its
exacerbations, the most commonly involved viruses
include respiratory syncytial virus (RSV), rhinovirus
(RV), influenza and parainfluenza viruses, corona-
virus, enterovirus, and adenovirus.8 Wheezing-
associated viral infections are characterized by an
age-related distribution. In particular, RSV predo-
minates in children under 3 years of age, whereas
RV represents the most frequent cause of infectious
respiratory illnesses affecting older children and
adults9; influenza and parainfluenza viruses affect
all age groups.Respiratory syncytial virus (RSV)
With regard to RSV, it is noteworthy to point out
that this virus infects about 70% of infants within
the first year of life, and almost 100% by the age of
3 years.10 RSV often produces only non-complicated
infections of the upper airways. Nevertheless, in
some cases RSV causes a severe bronchiolitis which
is frequently associated with the development of
recurrent wheezing and asthma. However, it is not
yet clear whether RSV constitutes a direct cause of
asthma, or if it rather induces airway obstruction
exclusively in individuals with a genetic predisposi-
tion to asthma. Therefore, it is very difficult to
establish whether the bronchiolitis caused by RSV
simply accelerates the onset of asthma, or if this
virus instead represents a crucial factor for the
subsequent development of the allergic sensitiza-
tion which characterizes many asthmatic patients.
In this regard, conflicting data have been indeed
provided by various studies, some of which have
allowed to detect, in contrast with others, a close
relationship between RSV-induced paediatric
bronchiolitis and the clinical manifestations of
atopy and asthma. For instance, Stein and collea-
gues carried out a wide perspective investigation
on more than 1000 children, studied since their
early infancy until the beginning of adolescence.
These authors found that the lower respiratory
tract infections caused by RSV within the first 3
years of age, though not so severe to require
hospitalization, were associated with an increased
risk of wheezing by the age of 6.11 However, such a
risk subsequently subsided progressively, thus re-
sulting to be not significant by the age of 13. On the
contrary, the Scandinavian group led by Sigurs
has more recently shown that children who
contracted a severe RSV infection within the
first year of life experienced, until the age of
about 7 years, a higher frequency of bronchial
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children not previously affected by a serious
bronchiolitis.12 Moreover, by continuing to follow-
up their study population, the same authors have
further confirmed that the risk of developing
allergic asthma persisted, until the age of 13, in
those subjects who were hospitalized during their
first year of life because of bronchiolitis produced
by RSV.13
Several cellular and molecular mechanisms might
contribute to determine an atopic phenotype in
children and adolescents with a history of severe
forms of bronchiolitis caused by RSV during early
childhood. Indeed, RSV may be responsible for an
increased risk of allergic sensitization by favouring
the creation of a bronchial and bronchiolar micro-
environment characterized by high levels of inter-
leukin-4 (IL-4).14 This cytokine represents the most
important factor determining the expansion of Th2
lymphocytes, the cells primarily implicated in the
pathogenesis of allergic processes. Furthermore,
IL-4 is directly responsible for the antibody class
switching which promotes the production of IgE by
B lymphocytes. The different biological behaviours
induced by RSV might be explained by the tendency
of most children with a common, mild RSV infec-
tion, to develop a predominantly Th1-mediated
antiviral immune response, characterized by an
intense production of interferon-g (IFN-g). Other-
wise, a Th2-dependent immune response asso-
ciated with high IL-4 levels can occur in very
young patients affected by severe bronchiolitis. In
this regard, it has been suggested that the
individual susceptibility to the development of
both allergic sensitization and serious respiratory
viral infections, may be due to genetic factors. In
particular, a genetically determined delay in the
physiological, early post-natal immune deviation
from the prevalent Th2 foetal pattern towards the
maturation of a Th1 phenotype, could predispose to
the amplification and propagation, within the
airways, of inflammatory events triggered by both
respiratory viruses and inhaled allergens.15 This
hypothesis has been confirmed by the high fre-
quency, recently shown in a population of 105
Korean children hospitalized for severe RSV infec-
tions, of a haplotype detected inside the cytokine
gene cluster located on the long arm of chromo-
some 5 (-589T IL-4 gene polymorphism), associated
with an overexpression of IL-4.16 Within such a
biological context, a key function is likely exerted
by a specific RSV glycoprotein, named protein G,
which is able to promote a Th2 immune response.17
In fact, by comparatively evaluating the conse-
quences of experimentally induced infections
caused by either normal or G protein-defectivestrains of RSV, it has been observed in mice that this
protein plays an essential role in producing airway
inflammation and functional respiratory impair-
ment, both evoked by wild-type RSV.18 Moreover,
the RSV-elicited activation of an antiviral protein
kinase may favour, in B cells, isotype switching to
IgE.19
Finally, it is also relevant that RSV may con-
tribute to airway neurogenic inflammation by
inducing the expression of bronchial NK-1 recep-
tors,20 stimulated by substance P. This effect
can thus lead to an amplification of the proin-
flammatory action of substance P, released by the
sensory endings of unmyelinated C-fibres. The
importance of such a mechanism is experimentally
supported by the demonstrated efficacy of the
monoclonal antibody palivizumab, directed against
the viral protein F, in reducing the excessive neural
inflammation found in the airways of RSV-infected
rats.21Rhinovirus (RV)
Differently from children under scholar age, during
the following periods of childhood and adoles-
cence, as well as in adults, about 60% of the viral,
upper respiratory tract infections involved in
asthma exacerbations, are caused by RV.8 There-
fore, this virus is not only responsible for the
common cold, but it also exerts a relevant
pathogenic action in acute asthma relapses. From
a clinical and functional point of view, airway
infection due to some particular RV strains, such as
the RV16 serotype, produces in allergic patients a
recrudescence of asthmatic and rhinitic symptoms,
a deterioration of respiratory function, and an
increase in bronchial hyper-responsiveness.22 The
latter may persist for several weeks. Indeed, it is
now strongly evident that RV, in addition to
infecting the upper airways, may also colonize the
lower respiratory tract.
The prevalent location of RV-dependent tissue
damage is represented by the bronchial epithelium,
whose remarkable fragility typical of asthma makes
it particularly susceptible to the viral cytotoxic
effect, which in turn further facilitates the
penetration of allergens and other noxious agents
thus triggering a positive feed-forward circuit. The
cytopathic action exerted by RV on airway epithe-
lial cells likely constitutes the initial event in
asthma exacerbations induced by this virus. The
airway epithelial receptor for most RV strains is
intercellular adhesion molecule-1 (ICAM-1), which
also significantly contributes to the pathogenesis of
allergic inflammation.23,24 Papi and Johnston25
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expression via activation of the transcription factor
nuclear factor-kappa B (NF-kB), thereby increasing
its own pathogenic potential. Moreover, Bianco and
colleagues have found that also IL-4 and other Th2
cytokines stimulate the airway epithelial expres-
sion of ICAM-1, thus increasing the susceptibility of
asthmatic patients to RV infections.26 On the other
hand, NF-kB is also involved in transcriptional
activation of many genes encoding proinflamma-
tory cytokines and chemokines. In this regard, it is
now clear that intracellular oxidant radicals play a
key role in RV-induced stimulation of NF-kB activity
occurring in bronchial epithelium.27 These recent
advances about the molecular mechanisms under-
lying the pathogenic action of RV have important
therapeutic implications, in that both corticoster-
oids and reducing agents are able to inhibit the
activation of transcription factors responsible for
the enhanced expression of proinflammatory genes
encoding adhesion molecules and various cyto-
kines.
In particular, airway epithelial cells react to RV
infection with an inflammatory response mediated
by an increased biosynthesis of interleukins (IL)-6,
8, and 16,28 involved in maturation of T and B
lymphocytes as well as in fibroblast proliferation
(IL-6), recruitment of neutrophils (IL-8), and
chemotaxis of eosinophils and monocytes (IL-16),
respectively. Bronchial epithelial cells infected by
RV also produce high amounts of the chemokines
eotaxin and RANTES (Regulated upon Activation,
Normal T-cell Expressed and Secreted),28 which
play a powerful chemotactic role in eosinophilic
airway infiltration. Furthermore, by stimulating the
epithelial production of fibroproliferative and
angiogenic factors such as the fibroblast growth
factor-2 (FGF-2), RV extends its actions to the
subepithelial layers, thus contributing to the
structural changes responsible for airway remodel-
ling, another essential component of asthma
phenotype. Therefore, RV affects the functions of
both resident and immune/inflammatory cells,
thereby further addressing the immune response
of atopic, asthmatic patients towards a predomi-
nant type 2 pattern, already characterized by an
increased secretion of IL-4. In these subjects, the
concomitant reduced production of type 1 cyto-
kines such as IFN-g, may explain at least in part the
defective antiviral defences. Asthma is also char-
acterized by an ineffective presentation of viral
antigens, that contributes to impair the immuno-
logical mechanisms aimed at neutralizing RV. The
resulting persistence of RV infection can thus lead
to an exacerbation of asthma symptoms and
bronchial hyper-responsiveness.29Influenza and parainfluenza viruses
The airway immune inflammation occurring in many
asthmatic patients can be further amplified by
acute viral infections caused by influenza viruses.
The latter often exacerbate respiratory symptoms
and bronchial responsiveness to allergic stimuli.
Utilizing an animal model of asthma, Dahl and
colleagues have recently shown that the influenza A
virus induces pulmonary changes which last for
several weeks after infection resolution.30 In
particular, these authors observed that a previous
flu infection was able to enhance the cellular
response to a subsequent allergen sensitization, as
it can be inferred from the increased numbers of
eosinophils, lymphocytes and macrophages, de-
tectable in the bronchoalveolar lavage fluid (BALF)
obtained from mice infected with influenza A virus
when compared with control animals undergoing
allergen sensitization, but not previously exposed
to viral infection. Influenza viruses also contribute
to increase neurally mediated bronchial hypertone,
in that viral neuraminidases degrade the sialic acid
residues of prejunctional muscarinic M2 recep-
tors.31 By inhibiting acetylcholine release from
postganglionic fibres, these cholinergic autorecep-
tors exert an inhibitory control on vagal neuro-
transmission, Therefore, the influenza virus-
dependent M2 receptor dysfunction is responsible
for an exaggeration of reflex parasympathetic
bronchoconstriction.
Endotracheal inoculation of parainfluenza virus
induces, in animal models, biological and histolo-
gical changes reminiscent of asthma. In particular,
this viral infection elicits an airway influx of
inflammatory cells, bronchial hyper-responsive-
ness, epithelial damage and bronchiolar fibrosis.
Such two latter alterations are likely due to an
increased production of transforming growth fac-
tor-b (TGF-b) from parainfluenza virus-stimulated
alveolar macrophages.32 In fact, it is well known
that TGF-b has fibrogenic properties and also
induces apoptosis of airway epithelial cells.33 This
suggests that the recurrence of parainfluenza virus
infections may contribute, in patients with asthma,
to the airway structural changes typical of the
disease and at least in part mediated by TGF-b.
Apoptosis of bronchial epithelial cells may be
viewed as a host attempt to limit viral replication,
but at the same time cell death is likely a major
determinant of the epithelial damage occurring in
asthma. Furthermore, epithelial loss might be the
main cause of the defective bronchial synthesis of
nitric oxide (NO), detected in association with the
parainfluenza virus-dependent increase in airway
hyper-responsiveness.
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With regard to the role of non-viral infections in
asthma inception and exacerbations, the atypical
bacteria Chlamydia pneumoniae and Mycoplasma
pneumoniae are currently believed to be the most
involved pathogens.34Chlamydia pneumoniae
C. pneumoniae is a Gram-negative, obligate in-
tracellular bacterium, entirely dependent on en-
ergy produced by infected host cells, where it
replicates forming characteristic cytoplasmic in-
clusions. Within the respiratory system, the main
cellular targets of this pathogen include epithelial
and endothelial cells, as well as monocytes/
macrophages. C. pneumoniae may cause infections
of the upper and lower respiratory tracts.35
Furthermore, recurrence and/or persistence of
respiratory infections caused by C. pneumoniae
are likely implicated in the development and
worsening of asthma.36 On the other hand, this
microbial agent is characterized by an innate
tendency to determine chronic infections, which
result to be particularly insidious in that they are
frequently quiescent and non-symptomatic. Sev-
eral different genetic and environmental factors,
also including coexistence of other diseases, smok-
ing habit, and the therapeutic use of corticoster-
oids, contribute to promote the persistence of C.
pneumoniae infectious capacity.
A number of epidemiological studies have shown
that many asthmatic patients have high serum
levels of both IgG and IgA anti-C. pneumoniae
antibodies, which can be considered as markers of
persistent infection. In particular, Hahn and col-
leagues were the first to identify a consistent
association between wheezing and anti-C. pneu-
moniae antibody titres in 365 subjects with
respiratory symptoms.37 Moreover, these authors
also demonstrated that Chlamydial infection was a
risk factor for asthma onset in adults. In fact,
within the study population, 9 of 19 symptomatic
asthmatics exhibited serologic evidence of either a
current or a recent infection caused by C.
pneumoniae. The same authors have further
extended their observations thus showing, in adult
patients with recently diagnosed asthma, the
existence of serologically positive, chronic respira-
tory Chlamydial infections.38 In addition, a recur-
rence of dyspnoeic episodes induced by C.
pneumoniae may precede the development of
chronic asthma in previously asymptomatic indivi-
duals.39 Cunningham et al.40 studied 108 asthmaticchildren for 13 months, thus showing that C.
pneumoniae-specific secretory IgA antibodies in
nasal aspirates were much more elevated in
subjects with frequent asthma exacerbations. The
latter subgroup of children also tended to maintain
a longer PCR positivity for C. pneumoniae, indica-
tive of a chronic infection. A further confirm of the
tight relationships linking the infections caused by
C. pneumoniae with asthma severity and exacer-
bations was provided by Cook and colleagues, who
demonstrated in a cohort of 169 asthmatic patients
that chronic, severe forms of asthma were corre-
lated to high serum concentrations of anti-C.
pneumoniae IgG and IgA antibodies.41 More re-
cently, Black et al. observed in 619 asthmatic
adults that elevated serum titres of anti-C.
pneumoniae IgG and IgA were directly associated
with the severity of asthma symptoms, as well as
with the use of high doses of inhaled corticoster-
oids.42 These same authors also detected an inverse
correlation between antibody levels and airway
calibre, assessed by measuring forced expiratory
volume in one second (FEV1). Therefore, it can be
argued that chronic Chlamydial infections are likely
associated with markers of asthma severity. With
regard to the relationships between allergen-
induced and infection-dependent asthma varieties,
von Hertzen and colleagues investigated 332 asth-
matic patients thus finding in non-atopic subjects
that their disease was significantly associated,
differently from atopic individuals, with high
concentrations of anti-C. pneumoniae IgG.43 How-
ever, it is currently not known whether the
association between respiratory Chlamydial infec-
tions and asthma is causal or coincidental.
In order to settle such a controversy, an useful
contribute might be provided by studies performed
on asthmatic patients infected by C. pneumoniae,
with the aim of evaluating the effects of anti-
biotics, especially macrolides. In this regard, Black
et al. showed a significant improvement in evening
peak expiratory flow when asthmatic subjects,
serologically positive for Chlamydial infection,
were treated for 6 weeks with roxithromycin
(150mg b.i.d.)44; subsequently to therapy cessa-
tion, there was a decrease in the differences
detected in comparison with asthmatic individuals
treated with placebo. Furthermore, in those
patients undergoing treatment with roxithromycin,
a tendency was found, though statistically not
significant, towards a reduction of asthma symp-
toms. Kraft and colleagues also demonstrated that
chlarithromycin, administered for 6 weeks (500mg
b.i.d.), elicited an increase in FEV1 and a decrease
in the bronchial expression of IL-5, but only in
subjects who were PCR-positive for C. pneumoniae
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the induced sputum obtained from asthmatic adults
treated for 8 weeks with chlarithromycin (200mg
b.i.d.), as reported by Amayasu et al., who also
found a decreased airway hyper-responsiveness in
the same patients.46 This latter effect was con-
firmed by Ekici and colleagues after 8 weeks of
treatment with azithromycin (250mg twice a
week), which however did not induce any FEV1
change.47 Moreover, Gotfried et al. have recently
shown that chlarithromycin (250mg b.i.d.), given
for 6 weeks to asthmatic individuals treated with
oral prednisone, allowed to reduce steroid dosage
without consequences on asthma symptoms and
respiratory function.48 In order to correctly inter-
pret all these data, it is however noteworthy that
macrolides appear to exert, independently from
their antimicrobial properties, a relevant anti-
inflammatory action.49
During the last few years, a considerable progress
has been made in our understanding of the cellular
and molecular events underlying the potential role
of C. pneumoniae in asthma pathogenesis. Gener-
ally, the development of diseases induced by
Chlamydial infections is dependent on immuno-
pathological mechanisms. In this regard, a 57–60-
kDa Chlamydial antigen, which is a member of the
hsp60 family of heat-shock proteins, seems to
possess remarkable immunogenic, proinflamma-
tory, and cytopathic properties.50 The immune
response to this protein is likely involved in tissue
damage caused by recurrent and persistent Chla-
mydial infections, and infected cells produce
proinflammatory cytokines such as tumour necrosis
factor-a (TNF-a), IL-1b, IL-6 and IL-8.36,51 In the
airways of asthmatic patients, macrophages and
bronchial epithelial cells infected by C. pneumo-
niae could continuously or repeatedly release the
hsp60 antigen, thus contributing to perpetuate and
amplify chronic inflammation, as well as to induce
the structural changes typical of asthma. By
activating NF-kB, in fact, hsp60 is able to stimulate
the transcription of genes encoding proinflamma-
tory cytokines and adhesion molecules.52 An im-
portant feature of the amino acid composition of
Chlamydial hsp60 is to share a high homology
sequence with the analogous human protein.
Therefore, the bacterial hsp60 might evoke an
autoimmune reaction, eventually persisting even
after infection eradication. Recently, an associa-
tion has been identified between adult-onset
asthma and specific antibodies against another
Chlamydial antigen, named hsp10.53 In this regard,
it is interesting to point out that a surprisingly
elevated percentage (65.8%) of asthmatic subjects,
who are serologically negative for Chlamydialinfections, exhibit an anti-hsp10 antibody re-
sponse.
Taken together, the above-mentioned immune-
inflammatory pathogenic mechanisms, triggered by
chronic infections caused by C. pneumoniae, may
thus increase airway susceptibility to other envir-
onmental stimuli such as allergens and viruses,
thereby accelerating asthma progression. There-
fore, within this context antibiotics could play a
very important therapeutic role, excellently dis-
cussed in recent reviews by Blasi et al.54 and
Cazzola et al.49
Mycoplasma pneumoniae
Both serological and epidemiological studies sug-
gest that infections caused by M. pneumoniae may
be implicated in the pathogenesis of asthma, also
regarding its exacerbations. For instance, Martin et
al. evidenced, in about half of 55 asthmatic
patients, a PCR-documented presence of M. pneu-
moniae, which was also associated with a higher
number of tissue mast cell in comparison with PCR-
negative subjects.55 Furthermore, administration
of chlarythromycin (500mg b.i.d. for 6 weeks) to
PCR-positive asthmatics can significantly improve
their respiratory function.45 M. pneumoniae may
also trigger Th2-like cytokine responses, associated
with elevated serum IgE concentrations. In experi-
mental animal models, mice infected with M.
pneumoniae may develop airway obstruction and
inflammation.56
Airway epithelium represents the most important
tissue target of M. pneumoniae. In vitro, cultured
bronchial epithelial cells respond to experimentally
induced M. pneumoniae infection by enhancing the
synthesis of IL-1b, IL-6, IL-8, TNF-a, RANTES, and
TGF-b.57,58 The increase in cell culture supernatant
levels of RANTES and TGF-b can be inhibited, as
shown by Dakhama and colleagues, by a treatment
with either erythromycin or dexamethasone.58 This
implies that in the airways both macrolides and
glucocorticoids are potentially very useful in pre-
venting the inflammatory and structural changes
caused by M. pneumoniae, and especially the TGF-
b-induced damage of bronchial epithelium.33,58Hygiene hypothesis and asthma
The remarkable increase in the prevalence of
allergies and asthma, occurred during the last
decades especially in the industrialized countries,
is frequently attributed to a group of factors which
as a whole are referred to the so-called ‘‘hygiene
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lifestyle of westernized societies characterized by
improved hygienic conditions and lowered risk of
infections, due to widespread vaccinations and
decreased overcrowding and family size, is respon-
sible for a reduced exposure to microbial agents
especially during infancy and childhood. The result
of such a ‘‘sterilized’’ environment would be a
reduced activation of the Th1-arm of adaptive
immunity, which is stimulated by viral and bacterial
infections. Indeed, viruses promote the production
of cytokines such as IFN-g, IL-12 and IL-18, that
orientate lymphocyte differentiation towards a Th1
pattern.61 A Th1 response is also favoured by high
doses of bacterial components such as lipopolysac-
caride (LPS), which activates the innate immune
system by interacting with the toll-like receptor 4
expressed by dendritic cells.62 Moreover, a delayed
hypersensitivity to Mycobacterium tuberculosis can
be associated with a low risk of atopy.63 Therefore,
a reduced Th1 activation due to a lack of infectious
stimuli may contribute to polarize the immune
response towards a Th2 phenotype, involved in the
development of allergic diseases and asthma.
However, recent epidemiological reports have
raised reasonable doubts about the supposed
protective role of infections on asthma inception
and development. For instance, a large study
carried out in Europe on more than 18,000 subjects
showed a direct, rather than inverse correlation
between the number of siblings and the presence of
asthma symptoms and functional pulmonary im-
pairment.64 Another investigation, performed on a
sample of almost 14,000 British children, did not
evidence any influence of pertussis vaccination on
allergy and asthma.65 The relationship between
asthma and bacterial endotoxin is also quite
intriguing. Studying 226 children under the age of
5 and with a familial history of atopy, Litonjua et
al. have recently demonstrated that exposure to
high concentrations of endotoxin in house dust was
associated with an increased risk of wheezing,
which however rapidly declined within a few
years.66 In this regard, a previous study had
detected a direct relationship between inhaled
endotoxin levels and the exacerbation of pre-
existing asthma symptoms.67 Despite the proposed
protective effect of tubercular infection against
allergy and asthma, no correlation was found
between atopy and delayed sensitization to tuber-
culin in a population of about 500 African children
from Gambia.68 On the other hand, an intradermal
injection of heat-killed Mycobacterium vaccae,
performed by Camporota et al. in allergic asth-
matic patients, did not elicit significant changes
with regard to early and late asthmatic reactions toallergen challenge, bronchial hyper-responsiveness
to histamine, serum IgE levels, and IL-5 production
from peripheral lymphocytes.69
Furthermore, Holtzman and colleagues have
recently proposed a new theory, decisively alter-
native to the hygiene hypothesis, according to
which both Th1 and Th2 branches of the adaptive
immune response would be implicated in asthma
pathogenesis.70,71 In particular, within a genetically
predisposed individual context, the asthmatic
phenotype would develop as a consequence of a
concomitant activation of allergic and antiviral
mechanisms. Indeed, respiratory viruses might
induce bronchial epithelial cells to produce IFN-g
and IL-12, thus favouring the creation within the
airways of a local environment characterized by a
Th1 immune pattern. At the same time, inhaled
allergens would promote a deviation of the immune
response towards a Th2 secretory profile, mainly
including IL-4, 5, 9, and 13. Therefore, the Th1 and
Th2 arms of the adaptive immune system, rather
than antagonizing and reciprocally inhibiting each
other, may contribute together to unveil and
amplify the asthmatic phenotype, featured by
chronic inflammation, bronchial hyper-responsive-
ness, and airway remodelling. This pathogenetic
theory appears to be also supported by the above-
mentioned data obtained by Dahl and colleagues30
These authors inoculated intranasally the influenza
A virus into some mice which subsequently under-
went, several weeks after viral infection, an
allergen sensitization. Under such experimental
conditions, the influenza A virus dramatically
increased the secretion of IFN-g from pulmonary
dendritic cells, thus inducing a strong Th1 re-
sponse. The latter did potentiate, rather than
inhibiting, the expansion of the Th2 lineage
triggered by the following allergic challenge.
Within genetically mediated host susceptibility,
the dual involvement of Th1 and Th2 cells activated
by viral agents and inhaled allergens, respectively,
may thus determine the immune-inflammatory
changes underlying asthma.
Taking together all these considerations, and
keeping in mind the complexity of the asthmatic
phenotype, it seems unlikely that the increased
prevalence of asthma in the industrialized world
may be uniquely due to a reduced exposure to
infections during childhood. However, the contro-
versial hygiene hypothesis could not be completely
inconsistent, but it probably needs to be revised
and referred only to a limited group of infectious
agents, such as Toxoplasma gondii, Helicobacter
pylori and Hepatitis A virus.72–74 The latter appears
in fact to play a relevant protective role against the
development of atopic disorders.74 In any case, a
ARTICLE IN PRESS
G. Pelaia et al.782growing body of both in vitro and in vivo evidence
does not corroborate the potential utility for
asthma prevention and treatment of the immunos-
timulatory approach, also based on the use of
unmethylated cytosine–guanosine (CpG) dinucleo-
tides derived from bacterial genomes.75 CpG DNA
sequences are potent inducers of the Th1 immune
response, which however could result to be not
completely effective in preventing or curing atopy
and asthma, in addition to representing an eventual
risk factor for the development of Th1-mediated
disorders like autoimmune diseases and diabetes.Conclusions
Respiratory infections may significantly affect, via
complex cellular and immunological mechanisms,
the development and progression of asthma, also
including its exacerbations. On the other hand,
routine clinical practice clearly indicates that such
infections often cause, in asthmatic patients, a
worsening of symptoms and a deterioration of
pulmonary function. Therefore, anti-bacterial
agents such as macrolides and fluoroquinolones
may represent a useful therapeutic tool in limiting
both the duration and severity of asthma exacer-
bations induced by atypical bacteria like Chlamy-
diae and Mycoplasms. Moreover, further progresses
may be achieved in asthma therapy if pharmacolo-
gical and immunological research efforts will
provide new molecules and vaccines, able to be
really effective against those viruses most com-
monly involved in inducing and exacerbating such a
widespread disease.References
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